Merck assigns Chimeric Antigen Receptor T-cell (CAR-T) rights to Intrexon

Merck, a leading science and technology company, today announced it has evolved its agreement with Intrexon Corporation (NASDAQ: XON) for the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, genetically engineered T-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news